Business Wire

MA-VALAMIS

24.9.2020 10:02:15 CEST | Business Wire | Press release

Share
Valamis’ Global Survey Reveals the State of Learning & Development in the Workplace 2020

Valamis , the global leader in digital learning technologies and workforce development, published results from the “Global Survey on the State of Learning & Development (L&D) in the Workplace Report ,” which includes over 3000 people across more than 20 industries were surveyed from entry-level to C-Suite executives in organizations from Finland, France, Germany, Netherlands, Sweden, the US, and the UK.

Valamis conducted its 2nd annual “Global Survey on the State of Learning & Development (L&D) in the Workplace Report”, collecting insight into the shifting global priorities, challenges, behaviors, attitudes, and technologies in use for corporate learning and development, with additional research into the impact of COVID-19.

The importance of learning & development in the workforce

Findings from the survey show that roughly 93% of respondents globally believe updating knowledge and skills are important to an organization’s success and more than 50% of executives and the C-Suite value skills development as extremely important to an organization’s future success. Although the importance of learning and development has been recognized in every country surveyed, over 74% of respondents believe their organizations are actively encouraging the workforce to develop their skills and nearly 56% of respondents had a dedicated person or team responsible for learning and development at their organization.

Time to learn

Despite the globally acknowledged importance of learning and development, for the second consecutive year conducting the survey, the biggest challenge plaguing learning and development within organizations is a lack of time or perceived time affluence with regards to learning. 48% of respondents globally denoted a lack of time as the biggest challenge for learning and development. Interestingly, survey participants at the executive and C-suite level note that they use their digital learning environment the most frequently (Nearly 30% using it every day) of all survey participants.

Tools in place for corporate learning

25% of respondents specify not having the right tools in place as one of the top three challenges for learning & development. Approximately 15% of respondents demarcate that their organization does not have a digital learning environment in place at their organization, and the Netherlands has the highest percentage of respondents of all the countries surveyed that specify they have a Learning Management System (LMS) (24%) or Learning Experience Platform (LXP or LEP) (20%) in place, whereas the United States (28%), United Kingdom (29%), and Germany (28%) have the highest percentages of respondents relying on online courses or Massive Open Online Courses (MOOCs). Finland has the highest number of respondents (18%) that suggest their organization has no digital learning tools in place.

COVID-19 & L&D

Approximately 70% of executives within the global survey express they value digital learning and development more as a result of COVID-19, and over 67% of all global participants in the survey believe digital learning and development can help minimize the effects of shocks and stresses of future events.

“2020 has been a challenging year for many organizations and individuals worldwide. Our global survey on the state of learning and development highlights an internationally growing acknowledgment from the C-suite that L&D is critical to the success of their organizations, and with the right tools in place organizations can adapt and reskill in the face of unforeseen events,” said Janne Hietala, Chief Visionary Officer, Valamis.

Download the report here .
*Please note the survey results are in English

About Valamis

Valamis is a digital learning company specializing in workforce development, and the developer of Valamis - Learning Experience Platform. Valamis' customers are large organizations spanning all industries—predominantly finance and insurance, complex manufacturing, and professional services. Headquartered in Joensuu, Finland, Valamis operates internationally with offices in the US, the UK, Germany, the Netherlands, Russia, and India.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 15:30:00 CEST | Press release

The collaboration expands FlexTrade’s front-office risk analytics offering, connecting portfolio construction, risk insight, and trading decisions in a unified buy-side workflow. FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and executio

Xsolla Connect Returns to Brighton13.7.2026 15:22:00 CEST | Press release

Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release

Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'

SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release

Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um

HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release

HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye